Study Links Immune Markers to Lung Cancer Immunotherapy Response

Researchers identified PET/CT scan changes and immune cell features that differed between patients who responded fully and those who retained residual cancer.

Updated on Nov. 11, 2026 in Cancer

Bold vector editorial illustration of a white imaging gantry beside a lab bench with a glass slide, in cool blues with coral accents.
A study of 13 lung cancer patients found PET/CT scan changes and immune-cell features that distinguished full responders to immunotherapy from those who kept residual cancer. AI Illustration. Upload story photo >

A study published in Translational Lung Cancer Research by researchers at Korea University Guro Hospital and the University of Auckland examined patients with stage 2 or 3 non-small cell lung cancer treated with preoperative immunotherapy. Eight of the 13 patients had a pathologic complete response, while five had residual cancer.

Why it matters

Identifying markers that indicate how a patient is responding to immunotherapy could help clinicians judge treatment effectiveness earlier. The findings are preliminary given the small number of participants.

The study enrolled 13 patients, with the tumor-to-liver uptake ratio on PET/CT dropping 82 percent in the eight patients who had a complete response compared with 58 percent in the five who kept residual cancer. Pretreatment tumor samples from complete-responders contained more CD4 T cells and more T cells expressing TIGIT, and the small sample size means these figures have not been confirmed in larger populations.

The players

Korea University Guro Hospital

A teaching hospital in Seoul, South Korea, affiliated with Korea University, that led the clinical work on this study.

University of Auckland

A public research university in Auckland, New Zealand, that co-led the study with the Korean hospital's researchers.

The details

The researchers compared PET/CT scans taken before and after immunotherapy and analyzed immune cells in tumor samples collected before treatment. Patients were treated at Korea University Guro Hospital between December 2017 and November 2023.

Timeline

  1. Patients were treated at Korea University Guro Hospital between December 2017 and November 2023.

  2. The study was published on November 11, 2026, in Translational Lung Cancer Research.

Big Picture

The work follows the neoadjuvant nivolumab approach tested in the CheckMate 816 trial, which showed improved pathologic response rates before surgery in resectable non-small cell lung cancer. The new study seeks the markers that could explain why some patients respond fully while others do not.

For patients with resectable lung cancer, markers that predict response to immunotherapy could eventually inform whether a treatment is working before surgery. The findings remain experimental and are not yet available as a clinical test.

The takeaway

Biomarkers from scans and tumor samples may eventually help clinicians tailor immunotherapy for lung cancer, but larger trials are needed before they change practice. Patients should discuss treatment response monitoring with their oncology team.

Further reading

Explore more on Cancer research and treatment developments.

Source note: This article includes information reported by Korea Biomedical Review.